BioAge Labs is scrapping a Phase 2 trial testing its anti-obesity drug, a few months after its flashy $198 million initial ...

The usual enhanced security measures are expected to be in place in San Francisco next month when the healthcare industry ...

Novartis’ Fabhalta improved hemoglobin levels in patients with a rare blood disorder who switched from anti-C5 therapies, ...

AstraZeneca and Daiichi Sankyo have unveiled new data on their TROP2-directed ADC in pretreated lung cancer patients with ...

The same day that National Resilience announced a new CEO, it said that it will cut more than 100 jobs in Florida. The ...

A UK political committee says the country is underprepared for future pandemics due to 'worrying developments' on domestic ...

Teva will sell its Japan business to JKI. Rome Therapeutics lays off 17 employees to focus on autoimmune and neurodegenerative diseases. Cyclacel reviews strategic alternatives, MediciNova reports ...

Duality Biologics and BioNTech say interim data on one of their partnered ADCs look encouraging, with a preliminary cut from the trial showing that nearly a third of treated patients had unconfirmed ...

Despite months of biopharma industry pushback, the European Commission has unconditionally approved Novo Holdings’ $16.5 ...

Wisconsin border in 'America's Dairyland,' Eli Lilly is staking one of its largest-ever manufacturing bets to continue its ...

GSK's BD team was busy leading up to the Thanksgiving holiday. In the last two days, the UK-based pharma has announced three ...

GSK revises deal with Chongqing Zhifei Biological Products, extending Shingrix distribution rights in China through 2034 but ...